Cytek Biosciences (CTKB) Stock Statistics & Valuation Metrics

Cytek Biosciences has a market cap or net worth of $572.10M. The enterprise value is $484.65M.

Cytek Biosciences has 129,142,600 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cytek Biosciences’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -10.28%.

The current PE Ratio of Cytek Biosciences is ―. Cytek Biosciences’s PEG ratio is -0.00942.

In the last 12 months, Cytek Biosciences had revenue of 201.49M and earned -66.54M in profits. Earnings per share was -0.52.

In the last 12 months, operating cash flow was -7.30M and capital expenditures -5.40M, giving a free cash flow of -12.70M billion.

Cytek Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Cytek Biosciences upcoming earnings date is Aug 12, 2026, After Close (Confirmed).

Cytek Biosciences as a current ratio of 5.04, with Debt / Equity ratio of 11.09%

In the past 12 months, Cytek Biosciences has paid 36.70M in taxes.

Cytek Biosciences EV to EBITDA ratio is -33.23, with an EV/FCF ratio of -65.91.

Cytek Biosciences has $262.23M in cash and marketable securities with $36.33M in debt, giving a net cash position of $225.90M billion.

Gross margin is 51.70%, with operating margin of -20.04%, and net profit margin of -33.02%.

The average price target for Cytek Biosciences is $5.69, which is 11.43% higher than the current price. The consensus rating is Moderate Buy